Las Vegas Sands stock slides as Macau margin jitters flare — what investors are watching next
9 January 2026
1 min read

Las Vegas Sands stock slides as Macau margin jitters flare — what investors are watching next

New York, January 9, 2026, 15:40 (EST) — Regular session

  • Las Vegas Sands shares fell about 4% in afternoon trade, lagging a firmer U.S. market.
  • Analysts pointed to fresh worries over Macau operating costs and fourth-quarter margins.
  • Focus is turning to the company’s next results update later this month.

Las Vegas Sands shares were down about 4.3% at $59.25 in afternoon trade on Friday, after touching a session low near $59.18.

The drop matters now because Sands is one of the U.S. market’s purest plays on Macau casinos, where small swings in costs and promotions can move profits quickly. Traders have been quick to fade anything that hints at weaker margins going into the next round of quarterly reports.

JPMorgan said it had been fielding calls from dozens of investors after shares of Hong Kong-listed Sands China fell 4.5% on Thursday, while Melco Resorts dropped 7%, with “no obvious negative event” behind the move. The bank wrote: “We’re not sure why the market would be pricing in this risk today,” while flagging concern around a possible fourth-quarter margin miss. 1

Citi analysts George Choi and Timothy Chau said higher operating costs in the December quarter may have blunted operating leverage in Macau, pointing to spending tied to events including the NBA China Games and the 15th National Games, plus disruption from satellite casino closures. They forecast industry EBITDA — earnings before interest, taxes, depreciation and amortisation, a common yardstick for operating profit — rising 13% year-on-year to $2.25 billion, assuming gaming revenue growth of about 15%, and put industry margins at 27.5%. 2

Other casino names with Macau exposure were also lower. Wynn Resorts fell about 0.5%, MGM Resorts slipped roughly 2% and Melco was down about 3.2%, while the S&P 500 ETF SPY rose about 0.8%.

Sands is still well below recent highs, and the stock is about 16% under its 52-week peak of $70.45 hit on Dec. 1, MarketWatch data showed. 3

Analysts expect Las Vegas Sands to earn about $0.78 per share for the December quarter, according to a recent Barchart earnings preview. Investors are likely to focus less on the headline profit number and more on any read-through on Macau cost control and promotional intensity.

But Macau remains a policy-driven market, and the downside case is not hard to sketch: costs stay sticky, customer mix shifts the wrong way, or fresh friction around cross-border travel and money flows chills demand. Any sign that Singapore slows would only add to the pressure.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings
Previous Story

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Why iRhythm stock is sliding today as Wall Street looks to JPM Healthcare Conference
Next Story

Why iRhythm stock is sliding today as Wall Street looks to JPM Healthcare Conference

Go toTop